Naoto Ueno, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the patient reported outcomes (PROs) from the randomized Phase III DESTINY-Breast04 (NCT03734029) trial of trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice in patients with HER2-low metastatic breast cancer (MBC). DESTINY-Breast04 demonstrated improved progression-free survival (PFS) and overall-survival (OS) of T-DXd in patients with HER-low MBC regardless of hormone receptor (HR) status. PROs were measured using the European Organization for Research and Treatment of Cancer QOL questionnaires and the EuroQol 5-dimension, 5-level visual analog scale. Patients who received T-DXd maintained GHS/QOL longer than treatment of physician’s choice in all prespecified QLQ-C30 subscales while on therapy. These results are consistent with the primary results and confirm the quality of life benefit of T-DXd versus treatment of physician’s choice for patients with HER2-low MBC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.